Alembic Pharma recieves EIR report for oncology drugs from USFDA

 Alembic Pharmaceuticals on Monday, May 6, announced that it has received an establishment inspection report (EIR) from the United States Food and Drug Administration for its oncology facility in Gujarat.

The pharma company, in a stock exchange filing, said that its oncology (injectable and oral solid) formulation facility located at Panelav in Panch Mahals district of Gujarat has received the EIR from the US drug regulator.

“The company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav,” the company said.

The inspection was carried out at the pharmaceutical company’s formulation facility from February 28 to March 8. The company also informed the bourses that the EIRs are in place for all of its USFDA facilities.